

Orchid Pharma's antibiotic Exblifeb receives European Medicines Agency approval

30 January 2024 | News

A significant development in addressing the global need for affordable and efficacious drugs to combat Anti-Microbial Resistance



Orchid Pharma, based in Chennai, has achieved a significant breakthrough with its antibiotic invention, Exblifeb, which incorporates Enmetazobactam, the first completely invented-in-India Beta Lactamase Inhibitor.

This pioneering drug recently received the European Medicines Agency's (EMA) recommendation for marketing authorisation, marking the first instance of an India-invented drug reaching this stage of clinical development.

Designed to address the global challenge of Anti-Microbial Resistance (AMR), 'Exblifeb' demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia, and bacteremia caused by Extended Spectrum Beta-lactamase producing pathogens.

During clinical trials, 'Exblifeb' exhibited superior performance compared to the current go-to drug, Piperacillin + Tazobactam. It is positioned as a potent, cost-effective, and Carbapenem-sparing therapy, offering a viable solution in the fight against rising AMR.

This milestone not only positions 'Exblifeb' as a front-runner in combating AMR but also underscores the urgent need for

effective solutions.

Enmetazobactam was invented in India by Orchid and then out-licensed to US-based Allegra Therapeutics for further development.